# OnCo record orimiracle-s (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/orimiracle-s/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "orimiracle-s" ;
  schema:name "OriMIRACLE S"@en ;
  schema:alternateName "OriMIRACLE"@en, "Minimal Residual Circulating Nucleic Acid Longitudinal Detection in Solid Tumor"@en, "OriMIRACLE S" ;
  schema:description "OrigiMed's personalised blood test for leftover cancer, which deliberately tracks only mutations shared by every tumour cell."@en ;
  schema:url <https://onco.cc/drugs/orimiracle-s/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1002/cam4.6286>, <https://doi.org/10.1016/j.eclinm.2024.102697> ;
  onco:status "emerging" ;
  onco:tag "test", "mrd" ;
  onco:modality "Tumour-informed ctDNA minimal residual disease test (clonal variants, multiplex PCR)" ;
  onco:related <https://onco.cc/drugs/signatera/> ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/osteosarcoma/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:companies <https://onco.cc/companies/origimed/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-qi-orimiracle-gastrointestinal-cancer-med-2023/>, <https://onco.cc/key-papers/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024/> .